← Eichor
Study identifier: NCT06731374 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Condition: Pneumococcal Disease · Pneumococcal Carriage  ·  Sponsor: University of Oxford

PhasePhase 4
Planned participants106
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersYes

About this study

Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the nasal microflora without causing harm. This is called "carriage". But the bacteria can still be passed on to other people. If they are at-risk, for example elderly, or very young, or have pre-existing health conditions, the pneumococcus bacteria can cause pneumonia, which can cause serious life-threatening illness. Pneumococcus bacteria are surrounded by a sugar capsule. But the capsule does not always have the same components. As a result, the bacteria are classified into more than 100 different types. To make them effective, the vaccines that are currently available contain the sugar capsules of the most common pneumococcal types that cause disease. One such vaccine - PCV13 - has been effective globally in protecting against pneumococcus disease. It works because it controls the "carriage" (how a person carries the bacteria in their nose) of 13 types of the bacteria. Vaccines giving protection against other types of the bacteria are also becoming available worldwide. PCV15 is similar to PCV13 and protects against two additional types of the bacteria so may offer more protection. This study, which lasts 2 months and is funded by Merck Sharp \& Dohme (MSD), aims to assess if using PCV15 can protect against "carriage". To do this, investigators will …

This description comes directly from the study's public registry record.

Talk to the study team

Carla Solorzano-Gonzalez, PhD  ·  +44 1865 611400  ·  Carla.SolorzanoGonzalez@paediatrics.ox.ac.uk

Simon Drysdale  ·  +44 1865 611400  ·  info@ovg.ox.ac.uk

Always discuss trial participation with your own doctor first.

Locations (2)

Liverpool Vaccine GroupLiverpool, North West, United KingdomRecruiting
Oxford Vaccine GroupOxford, Oxfordshire, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06731374